Doxorubicin of Boryung Pharm to obtain COS in Europe

Boryung Pharm has recently won the Certificate of Suitability (COS) of doxorubicin, antineoplastic substance, which was successfully developed via its own fermentation process for the third time in the world. It plans to make its indirect export through Helm of Germany, while moving forward its direct export towards Europe, South America and Japan.

To this end, Boryung completed a 3-tower GM...